Russia’s sovereign wealth fund and Serum Institute of India have announced plans to start the production of the Sputnik V vaccine in India.
The first batch of Sputnik V vaccine is expected to be produced at the Serum Institute’s facilities starting September.
They intend to produce over 300 million doses of the vaccine in India per year.
As part of the technology transfer process, SII has already received cell and vector samples from the Gamaleya Centre.
With their import approved by the Drug Controller General of India, the cultivation process has also begun.